Avandia panel member may be investigated for possible conflicts of interestBMJ 2010; 341 doi: http://dx.doi.org/10.1136/bmj.c4083 (Published 03 August 2010) Cite this as: BMJ 2010;341:c4083
- Janice Hopkins Tanne
- 1New York
The US Food and Drug Administration has asked its parent department to investigate possible conflicts of interest relating to one of the members of the panel that recently recommended further restrictions on the drug rosiglitazone (marketed as Avandia), manufactured by GlaxoSmithKline (GSK) and used to control type 2 diabetes (BMJ 2010;341:c3862, 16 Jul, doi:10.1136/bmj.c3862).
After an internal review of disclosure forms the FDA asked the Office of the Inspector General of the Department of Health and Human Services to investigate disclosure or non-disclosure of conflicts of interest by the panel member David …
Log in using your username and password
Log in through your institution
Sign up for a free trial